Isotope

Westchester Medical Center to Debut ZAP-X Gyroscopic Radiosurgery System, Marking a Milestone for New York

Retrieved on: 
Tuesday, January 16, 2024
Radiology, Surgery, Oncology, Health, Medical Devices, Robotics, Hospitals, Technology, Brain, Radiation, Patient, Neoplasm, MD, Isotope, Westchester Medical Center, Multimedia, Neck, Hudson Valley, Stereotactic surgery, Brainstem, Head, Cranial nerves, SRS, Medical imaging

Westchester Medical Center, the flagship academic medical center for the Westchester Medical Center Health Network (WMCHealth), is set to become the first hospital in New York State to introduce the non-invasive surgical robotics platform, the ZAP-X® Gyroscopic Radiosurgery®, which will transform brain cancer treatments for patients throughout the Hudson Valley.

Key Points: 
  • Westchester Medical Center, the flagship academic medical center for the Westchester Medical Center Health Network (WMCHealth), is set to become the first hospital in New York State to introduce the non-invasive surgical robotics platform, the ZAP-X® Gyroscopic Radiosurgery®, which will transform brain cancer treatments for patients throughout the Hudson Valley.
  • Installation of the ZAP-X platform is expected to commence in mid-2024.
  • Typically completed in less than five brief outpatient visits, patients often resume their normal activities on the same day as the procedure.
  • This innovative method aims to improve patient outcomes by enhancing the ability to avoid critical structures like the brain stem, eyes, and optic nerves.

ASP Isotopes Inc. Provides Corporate Update

Retrieved on: 
Wednesday, January 10, 2024
Laser, ASPI, Isotope, ASP, Microsoft, Small modular reactor, FDA, HALEU, Rare-earth element

WASHINGTON, Jan. 10, 2024 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes” or the “Company”), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, today provided a corporate update regarding the Company’s operations in Pretoria, South Africa.

Key Points: 
  • -Commenced the construction of the Company’s third isotope enrichment facility in South Africa, for the production of Ytterbium-176.
  • Expects the facility to have production capacity of kilogram quantities of 99.55% 176Yb, and to commence operations in 2025.
  • WASHINGTON, Jan. 10, 2024 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes” or the “Company”), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, today provided a corporate update regarding the Company’s operations in Pretoria, South Africa.
  • Quantum Enrichment utilizes lasers and is intended to revolutionize isotope production of certain isotopes such as Ytterbium-176, Nickel-64, HALEU and Lithium-6.

Perspective Therapeutics Enters into Strategic Agreements with Lantheus Including Equity Investment, Co-Development Options, and Expansion of Manufacturing Capability

Retrieved on: 
Tuesday, January 9, 2024
Glomus tumor, Patient, Therapy, Isotope, Cancer, CATX, Sale, GRPR, IND, Acquisition, LNTH, Toxicity, PSMA, Radionuclide, File, Medical imaging

Perspective Therapeutics agrees to acquire radiopharmaceutical manufacturing facility in Somerset, New Jersey

Key Points: 
  • Perspective Therapeutics agrees to acquire radiopharmaceutical manufacturing facility in Somerset, New Jersey
    SEATTLE, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), today announced it entered into strategic agreements with Lantheus Holdings, Inc., the leading radiopharmaceutical-focused company, and its affiliates (Lantheus) (NASDAQ: LNTH).
  • Additionally, Perspective has agreed to acquire the assets and associated lease of Lantheus’ radiopharmaceutical manufacturing facility in Somerset, New Jersey for an undisclosed price.
  • Thijs Spoor, Chief Executive Officer of Perspective, stated, "At Perspective Therapeutics, our goal is to leverage the best isotopes and provide effective therapeutic choices for patients with difficult-to-treat cancers.
  • The closing of Perspective’s acquisition of the Somerset facility and related assets is subject to customary closing conditions, including regulatory approval.

Nuclear Medicine/ Radiopharmaceutical/Logistic - Loos, France, RLG, Isovital Headquarter, Jan 8th 2024 : “Life Couriers acquires Isovital and the RLG group to create the global logistic leader for radiopharmaceuticals transportation”.

Retrieved on: 
Monday, January 8, 2024
Acquisition, Nuclear medicine, Isotope, RLG, Patient, Medicine

Philippe Sueur, Isovital President stated: « Significant efforts were needed to create the RLG group with Isovital, Isolife and Isotopes Services and it is quite satisfying to realize our group’s contribution today to help people live longer thru a full commitment to our key and faithful partners and customers.

Key Points: 
  • Philippe Sueur, Isovital President stated: « Significant efforts were needed to create the RLG group with Isovital, Isolife and Isotopes Services and it is quite satisfying to realize our group’s contribution today to help people live longer thru a full commitment to our key and faithful partners and customers.
  • I heartly thank them as I thank warmly as well our dedicated teams and employees.
  • The future of the newly formed group looks even brighter and thanks to its new global footprint, and dedication to support our customers, the RLG will continue to evolve significantly in the coming months and years ».
  • Stefan Glebke, Life Couriers CEO added : “ I’m thrilled with ISOVITAL, ISOLIFE And ISI’s acquisition by our group as it demonstrates our full commitment to serve our customers and their patients all over the world.

Novartis expands production of Pluvicto™ with addition of its largest and most advanced radioligand therapy manufacturing facility in Indianapolis

Retrieved on: 
Friday, January 5, 2024
Marketing, Regulation, Food, INN, Pandemic, Sale, Government, Physician, Research, FDA, Breast, Lung, USAN, Lutetium, Prostate cancer, DOTA-TATE, Clinical trial, Lutetium (177Lu) oxodotreotide, Ligand, RLT, Isotope, Pancreatic cancer, Prostate, Cancer, Growth, Cell, Patient, Diagnosis, Safety, Pharmaceutical industry

The 70,000-square foot site, the company’s second US location, is designed specifically for RLT manufacturing and is now the largest and most advanced Novartis facility of its kind in the world.

Key Points: 
  • The 70,000-square foot site, the company’s second US location, is designed specifically for RLT manufacturing and is now the largest and most advanced Novartis facility of its kind in the world.
  • The Indianapolis site represents the next phase of RLT manufacturing growth as this new addition brings substantial supply increases for the foreseeable future.
  • “The intricate process of providing RLTs to patients within hours of production requires precision manufacturing expertise to bring these medicines to individuals who critically need them,” said Steffen Lang, President, Operations, Novartis.
  • Novartis is committed to expanding the radioligand therapy platform to shape the future of RLT as a treatment class.

Curio and Deep Isolation Sign MOU to Advance Nuclear Waste Disposal Technologies.

Retrieved on: 
Thursday, December 7, 2023
Partnership, Recycling, Deep geological repository, UCS, HLW, MOU, Knowledge, Isotope, Transport, ARPA, UNF, Universal

Washington, D.C., Dec 8, 2023 - (ACN Newswire) - Curio, a trailblazer in nuclear technology solutions, and Deep Isolation, an innovator in nuclear waste disposal, have entered into a Memorandum of Understanding (MOU) to collectively drive forward the development of advanced technologies for efficient and secure disposal of high-level nuclear waste (HLW).

Key Points: 
  • Washington, D.C., Dec 8, 2023 - (ACN Newswire) - Curio, a trailblazer in nuclear technology solutions, and Deep Isolation, an innovator in nuclear waste disposal, have entered into a Memorandum of Understanding (MOU) to collectively drive forward the development of advanced technologies for efficient and secure disposal of high-level nuclear waste (HLW).
  • Deep Isolation is the owner and developer of a suite of technologies for deep borehole storage and disposal of used nuclear fuel and other nuclear waste.
  • This strategic partnership combines Curio's expertise in advanced nuclear recycling technology with Deep Isolation's pioneering solutions for nuclear waste disposal.
  • Elizabeth Muller, CEO of Deep Isolation, remarked, "We're excited to work with the Curio team to address waste disposal requirements from nuclear fuel recycling.

US Nuclear’s Partner MIFTI Reports Break Out Fusion Power Test Results on the 4 Mega Ampere Machine at L3 Harris Lab

Retrieved on: 
Tuesday, December 26, 2023
Microsoft, Neutron, Helion Energy, Energy, US Nuclear Corp, UC, Isotope, University of California, Irvine, Lithium

US Nuclear is a partner, investor, and possible prime contractor for MIFTI’s fusion power generator, and is looking forward to further developments.

Key Points: 
  • US Nuclear is a partner, investor, and possible prime contractor for MIFTI’s fusion power generator, and is looking forward to further developments.
  • Continuing breakthroughs in technology and a large influx of funding have rapidly accelerated fusion power development.
  • Investment in the global fusion industry has skyrocketed, reaching a cumulative $6.21 billion, up from 4.8 billion just a year ago.
  • These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.

Perspective Therapeutics Divests Brachytherapy Business

Retrieved on: 
Tuesday, December 12, 2023
Brain, Tax, Lead, Intellectual property, Perspective, Sale, Seed, Software, Acquisition, Lung, Therapy, Neuroendocrine tumor, Isotope, Prostate, Brachytherapy, Patient, CATX, Radiation

SEATTLE, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced it agreed to fully divest its brachytherapy business, including its radioactive Cesium-131 seed assets and related business infrastructure, to GT Medical Technologies, Inc. (“GT Medical”).

Key Points: 
  • SEATTLE, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced it agreed to fully divest its brachytherapy business, including its radioactive Cesium-131 seed assets and related business infrastructure, to GT Medical Technologies, Inc. (“GT Medical”).
  • “At Perspective Therapeutics, we are relentlessly focused on realizing the therapeutic potential for the best possible isotopes that can be used to benefit patients with difficult-to-treat oncological indications," said Perspective Therapeutics CEO Thijs Spoor.
  • “The sale of our brachytherapy business marks a key strategic re-prioritization that allows us to focus on and dedicate resources towards accelerating the clinical development of our proprietary alpha-particle therapy portfolio.
  • “As a longstanding customer, we are impressed by the infrastructure that Perspective Therapeutics established for its Cesium-131 brachytherapy business,” said GT Medical Technologies CEO Matthew Likens.

Nusano to Host December 19 Virtual KOL Event on Emerging Trends in Radiotherapeutics

Retrieved on: 
Tuesday, December 12, 2023
Attention, Radionuclide, Cancer, Isotope, Regulatory affairs, Quality assurance, Patient, Therapy, KOL

They will discuss emerging trends in the radiotherapeutics landscape, a market that is projected to have a $30 billion potential in the next five years, a prospect that is capturing the attention of investors and companies alike.

Key Points: 
  • They will discuss emerging trends in the radiotherapeutics landscape, a market that is projected to have a $30 billion potential in the next five years, a prospect that is capturing the attention of investors and companies alike.
  • The event will highlight the isotopes that are the next frontier in radiotherapeutics development, exploring alternatives to industry staples like Lutetium-177 and Actinium-225.
  • Additionally, the discussions will delve into supply chain complexities, the role of CDMOs in bringing radiotherapeutics to patients, and the optimal timing for commercial-scale product development.
  • Nusano’s production platform enables the creation of rare and hard-to-produce medical radioisotopes in quantities needed for commercial-stage diagnostics and therapeutics.

General Atomics Brings Inertial Fusion Energy Expertise to Two National Research Hubs

Retrieved on: 
Friday, December 8, 2023
Ignition, Massachusetts Institute of Technology, Fusion rocket, Workforce, LEI, Isotope, General Atomics, UCLA, Science, LLNL, Inertial confinement fusion, Energy, NRL, MIT, Capsule, Cornell University, Savannah River National Laboratory, United States national laboratories, SRNL, ICF, University, Seawater, UCSD, UCB, DOE, University of Oklahoma, University of Illinois Urbana-Champaign, Texas A&M University, University of California, Berkeley, LANL, Hydrogen, Laser, CSU, SLAC National Accelerator Laboratory, Colorado State University, Los Alamos National Laboratory, Oak Ridge National Laboratory

San Diego, CA, Dec. 08, 2023 (GLOBE NEWSWIRE) -- General Atomics (GA) has been selected as a team member for two science and technology hubs funded by the U.S. Department of Energy (DOE)’s Inertial Fusion Energy Science & Technology Accelerated Research ( IFE-STAR ) program to advance IFE science and technologies.

Key Points: 
  • San Diego, CA, Dec. 08, 2023 (GLOBE NEWSWIRE) -- General Atomics (GA) has been selected as a team member for two science and technology hubs funded by the U.S. Department of Energy (DOE)’s Inertial Fusion Energy Science & Technology Accelerated Research ( IFE-STAR ) program to advance IFE science and technologies.
  • The STARFIRE and RISE hubs will each receive $16 million each over the next four years.
  • IFE is currently the only fusion approach to have achieved net energy gain in a laboratory, after achieving a 1.5x energy gain at LLNL’s National Ignition Facility (NIF) in December 2022.
  • Other collaborators working on the RISE hub include CSU, Stanford & SLAC National Accelerator Lab, University of Illinois, Cornell University, Texas A&M, Los Alamos National Lab (LANL), Naval Research Lab (NRL), Marvel Fusion (MF), and Xcimer Energy.